Mark W. Kieran

DEVELOPMENT OF A FIVE-GENE HEDGEHOG SIGNATURE AS A PATIENT PRESELECTION TOOL FOR HEDGEHOG PATHWAY-TARGETED THERAPY IN MEDULLOBLASTOMA

Keith L. Ligon, Douglas Robinson, Jordi Rodon, 2013 .

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

Keith L. Ligon, Sandro Santagata, Mark A. Rubin, 2009, PloS one.

MB-70MEMMAT - A PHASE II STUDY OF METRONOMIC AND TARGETED ANTI-ANGIOGENESIS THERAPY FOR CHILDREN WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA

Andreas Peyrl, Thomas Czech, Christine Haberler, 2016 .

Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment

Donna Neuberg, Nicole J. Ullrich, David T. Miller, 2013, Neurology.

Identification of fibroblast heterogeneity in the tumor microenvironment

Mark W. Kieran, Raghu Kalluri, Hikaru Sugimoto, 2006, Cancer biology & therapy.

Challenges to curing primary brain tumours

Giles W. Robinson, Paul Workman, Amar Gajjar, 2019, Nature Reviews Clinical Oncology.